Research Analysts Issue Forecasts for Omnicell Q1 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research boosted their Q1 2025 earnings per share estimates for Omnicell in a research note issued on Thursday, November 14th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.15 per share for the quarter, up from their prior forecast of $0.14. The consensus estimate for Omnicell’s current full-year earnings is $0.74 per share. Zacks Research also issued estimates for Omnicell’s Q2 2025 earnings at $0.18 EPS.

Several other research analysts have also recently commented on the stock. Benchmark reiterated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Craig Hallum raised their target price on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Bank of America reissued a “neutral” rating and set a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Omnicell presently has an average rating of “Hold” and an average price target of $50.83.

Omnicell Stock Up 0.8 %

NASDAQ:OMCL opened at $46.05 on Monday. The stock has a fifty day simple moving average of $44.20 and a 200 day simple moving average of $36.96. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -118.07, a price-to-earnings-growth ratio of 43.97 and a beta of 0.81. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74.

Institutional Trading of Omnicell

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after purchasing an additional 80,312 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after buying an additional 508,789 shares in the last quarter. Champlain Investment Partners LLC increased its holdings in Omnicell by 16.0% in the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after buying an additional 241,235 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after acquiring an additional 3,570 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.